Clinic Roundup

 Reviva Pharmaceuticals Inc., of San Jose, Calif., said it completed patient enrollment in its Phase II study of RP5063 in schizophrenia and schizoaffective disorder. The trial enrolled a total of 234 patients, with top-line data expected by the end of February.